List of Excipients in API METYRAPONE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing METYRAPONE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| ESTEVE PHARMACEUTICALS SA | METOPIRONE | metyrapone | 68118-455 | 4-ACETYLANISOLE | |
| ESTEVE PHARMACEUTICALS SA | METOPIRONE | metyrapone | 68118-455 | ETHYL VANILLIN | |
| ESTEVE PHARMACEUTICALS SA | METOPIRONE | metyrapone | 68118-455 | GELATIN | |
| ESTEVE PHARMACEUTICALS SA | METOPIRONE | metyrapone | 68118-455 | GLYCERIN | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for METYRAPONE
Excipient focus: 4-ACETYLANISOLE
METYRAPONE drug variants containing 4-ACETYLANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing 4-ACETYLANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ETHYL VANILLIN
METYRAPONE drug variants containing ETHYL VANILLIN
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing ETHYL VANILLIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ETHYLPARABEN SODIUM
METYRAPONE drug variants containing ETHYLPARABEN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing ETHYLPARABEN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
METYRAPONE drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERIN
METYRAPONE drug variants containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
METYRAPONE drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
METYRAPONE drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN SODIUM
METYRAPONE drug variants containing PROPYLPARABEN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing PROPYLPARABEN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM ETHYLPARABEN
METYRAPONE drug variants containing SODIUM ETHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing SODIUM ETHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
METYRAPONE drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
METYRAPONE drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| ESTEVE PHARMACEUTICALS SA | metyrapone | 68118-455 |
| HRA Pharma Rare Diseases | metyrapone | 76336-455 |
| >Company | >Ingredient | >NDC |
METYRAPONE drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch